ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.
2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.
   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.
   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.
   This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)  
   Lizza

2. Surname (Last Name)  
   Hendriks

3. Date  
   06-May-2020

4. Are you the corresponding author?  
   ✔ Yes  ❌ No

5. Manuscript Title  
   Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

6. Manuscript Identifying Number (if you know it)  
   TLCR-20-343

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  
Are there any relevant conflicts of interest?  
   ✔ Yes  ❌ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add +” box. You should report relationships that were present during the 36 months prior to publication.  
Are there any relevant conflicts of interest?  
   ✔ Yes  ❌ No
If yes, please fill out the appropriate information below.

| Name of Entity                  | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments                                           |
|---------------------------------|--------|----------------|------------------------|--------|---------------------------------------------------|
| boehringer ingelheim           | ❌      | ❌             | ✔                      | ✔      | fees for institution for advisory board           |
| BMS                             | ❌      | ❌             |                        | ✔      | fees for institution for advisory board           |
| Roche Genentech                 | ❌      | ❌             |                        | ✔      | travel support (self), ad board (institution)     |
| BMS                             | ❌      | ❌             |                        | ✔      | travel support (self)                             |
| Roche Genentech                 | ✔      | ❌             |                        |        | research funding (institution)                    |
| Boehringer Ingelheim            | ✔      | ❌             |                        |        | research funding (institution)                    |
ICMJE Form for Disclosure of Potential Conflicts of Interest

| Name of Entity             | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments |
|----------------------------|--------|----------------|------------------------|--------|----------|
| AstraZeneca                |        |                |                        |        |          |
| Quadia                     |        |                |                        |        |          |
| Astra Zeneca               |        |                |                        |        |          |
| Eli Lilly                  |        |                |                        |        |          |
| Roche Genentech            |        |                |                        |        |          |
| Pfizer                     |        |                |                        |        |          |
| MSD                        |        |                |                        |        |          |
| Takeda                     |        |                |                        |        |          |
| AstraZeneca                |        |                |                        |        |          |
| Novartis                   |        |                |                        |        |          |
| BMS                        |        |                |                        |        |          |
| MSD /Merck                 |        |                |                        |        |          |
| GSK                        |        |                |                        |        |          |
| Takeda                     |        |                |                        |        |          |
| Blueprint Medicines        |        |                |                        |        |          |
| Roche Genentech            |        |                |                        |        |          |

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  

- [ ] Yes  
- [x] No
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Hendriks reports other from boehringer ingelheim, other from BMS, other from Roche Genentech, other from BMS, grants from Roche Genentech, grants from Boehringer Ingelheim, other from AstraZeneca, personal fees from Quadia, grants from Astra Zeneca, other from Eli Lilly, other from Roche Genentech, other from Pfizer, other from MSD, other from Takeda, non-financial support from AstraZeneca, non-financial support from Novartis, non-financial support from BMS, non-financial support from MSD /Merck, non-financial support from GSK, non-financial support from Takeda, non-financial support from Blueprint Medicines, non-financial support from Roche Genentech, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
ICMJE Form for Disclosure of Potential Conflicts of Interest

1. **Identifying information.**

2. **The work under consideration for publication.**

   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. **Relevant financial activities outside the submitted work.**

   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. **Intellectual Property.**

   This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. **Relationships not covered above.**

   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

**Definitions.**

- **Entity:** government agency, foundation, commercial sponsor, academic institution, etc.
- **Grant:** A grant from an entity, generally [but not always] paid to your organization
- **Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations
- **Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
- **Other:** Anything not covered under the previous three boxes
- **Pending:** The patent has been filed but not issued
- **Issued:** The patent has been issued by the agency
- **Licensed:** The patent has been licensed to an entity, whether earning royalties or not
- **Royalties:** Funds are coming in to you or your institution due to your patent
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)  Jordi
2. Surname (Last Name) Remon
3. Date 06-May-2020
4. Are you the corresponding author?  Yes  No
5. Manuscript Title
   Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
6. Manuscript Identifying Number (if you know it)
   TLCR-20-343

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest?  Yes  No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication. Are there any relevant conflicts of interest?  Yes  No

| Name of Entity | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments              |
|----------------|--------|----------------|------------------------|--------|-----------------------|
| OSE PHARMA     |  ☐     |  ☐             |  ☐                     |  ✔     | TRAVEL / ACOMMODATION |
| AstraZeneca    |  ☐     |  ☐             |  ☐                     |  ✔     | ADVISORY              |
| MSD            |  ☐     |  ☐             |  ☐                     |  ✔     | TRAVEL 7 ADVISORY     |
| Pfizer         |  ☐     |  ☐             |  ☐                     |  ✔     | ADVISORY              |
| Roche          |  ☐     |  ☐             |  ☐                     |  ✔     | TRAVEL                |
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 4. Intellectual Property -- Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):
☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. REMON reports other from Ose Pharma, other from AstraZeneca, other from MSD, other from Pfizer, other from Roche, outside the submitted work; .

Evaluation and Feedback
Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. **Identifying information.**

2. **The work under consideration for publication.**

   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”.

3. **Relevant financial activities outside the submitted work.**

   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. **Intellectual Property.**

   This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. **Relationships not covered above.**

   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

**Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent
ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. **Given Name (First Name)**
   - Jessica

2. **Surname (Last Name)**
   - Menis

3. **Date**
   - 06-May-2020

4. **Are you the corresponding author?**
   - Yes ☑ No

   **Corresponding Author’s Name**
   - Lizza Hendriks

5. **Manuscript Title**
   - Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

6. **Manuscript Identifying Number (if you know it)**
   - TLCR-20-343

### Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☑ Yes ☐ No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add +” box. You should report relationships that were present during the 36 months prior to publication.

Are there any relevant conflicts of interest? ☑ Yes ☐ No

If yes, please fill out the appropriate information below.

| Name of Entity      | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments                                           |
|---------------------|--------|----------------|-------------------------|--------|----------------------------------------------------|
| Boehringer-Ingelheim| ☑      | ☑             | ☐                       | ☑      | advisory, speaker, travel/conference reimbursement, fees for educational webinar |
| MSD                 | ☑      | ☐             | ☐                       | ☑      | advisory, speaker, travel/conference reimbursement |
| Roche               | ☑      | ☐             | ☐                       | ☑      | advisory, speaker, travel/conference reimbursement |
| Astrazeneca         | ☑      | ☐             | ☐                       | ☑      | speaker                                            |
| Ipsen               | ☑      | ☐             | ☐                       | ☑      | travel/conference reimbursement                    |
| BMS                 | ☑      | ☐             | ☐                       | ☑      | travel/conference reimbursement                    |
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Menis reports grants, personal fees and other from Boehringer-Ingelheim, grants and other from MSD, grants and other from Roche, grants and other from Astrazeneca, grants and other from Ipsen, grants and other from BMS, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
ICMJE Form for Disclosure of Potential Conflicts of Interest

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name) Benjamin
2. Surname (Last Name) Besse
3. Date 06-May-2020
4. Are you the corresponding author? Yes No

Corresponding Author’s Name L. Hendriks

5. Manuscript Title
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
6. Manuscript Identifying Number (if you know it) TLCR-20-343

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? Yes No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add +” box. You should report relationships that were present during the 36 months prior to publication.

Are there any relevant conflicts of interest? Yes No
If yes, please fill out the appropriate information below.

| Name of Entity          | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments                                           |
|-------------------------|--------|----------------|------------------------|--------|---------------------------------------------------|
| Abbvie                  | ✔      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Amgen                   | ✔      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Astra Zeneca            | ✔      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Biogen                  | ✔      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Blueprint medicines     | ✔      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
# ICMJE Form for Disclosure of Potential Conflicts of Interest

| Name of Entity         | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments                                                |
|------------------------|--------|----------------|------------------------|--------|--------------------------------------------------------|
| BMS                    | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Celgene                | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Eli Lilly              | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| GSK                    | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Ignyta                 | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| IPSen                  | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Merck / MSD            | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Nektar                 | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Onxeo                  | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Pfizer                 | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Pharma Mar             | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Sanofi                 | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Spectrum Pharmaceuticals| ☑   | ☐            | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Takeda                 | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Tiziana Pharma         | ☑      | ☐             | ☐                      | ☐      | Institutional grants for clinical and translational research |
| Nerviana               | ☐      | ☐             | ☑                      | ☐      | Investigator or co-investigator of trials               |
| GSK                    | ☐      | ☐             | ☑                      | ☐      | Investigator or co-investigator of trials               |
| Pfizer                 | ☐      | ☐             | ☑                      | ☐      | Investigator or co-investigator of trials               |
| Roche-Genentech        | ☐      | ☐             | ☑                      | ☐      | Investigator or co-investigator of trials               |
| Lilly                  | ☐      | ☐             | ☑                      | ☐      | Investigator or co-investigator of trials               |
| OSE pharma             | ☐      | ☐             | ☑                      | ☐      | Investigator or co-investigator of trials               |
ICMJE Form for Disclosure of Potential Conflicts of Interest

| Company                | Relationship Status | Investigator or co-investigator of trials |
|------------------------|---------------------|------------------------------------------|
| MSD                    | ☐ ☐ ✔ ☐             | Investigator or co-investigator of trials|
| Cellgene               | ☐ ☐ ✔ ☐             | Investigator or co-investigator of trials|
| Stemcentrx             | ☐ ☐ ✔ ☐             | Investigator or co-investigator of trials|
| Ignyta                 | ☐ ☐ ✔ ☐             | Investigator or co-investigator of trials|
| Abbvie                 | ☐ ☐ ✔ ☐             | Investigator or co-investigator of trials|
| Loxo Oncology          | ☐ ☐ ✔ ☐             | Investigator or co-investigator of trials|
| AstraZeneca            | ☐ ☐ ✔ ☐             | Investigator or co-investigator of trials|
| Blueprint Medicines    | ☐ ☐ ✔ ☐             | Investigator or co-investigator of trials|

**Section 4. Intellectual Property -- Patents & Copyrights**

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ✔ No

**Section 5. Relationships not covered above**

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

✔ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Dr. Besse reports grants from Abbvie, grants from Amgen, grants from Astra Zeneca, grants from Biogen, grants from Blueprint medicines, grants from BMS, grants from Celgene, grants from Eli Lilly, grants from GSK, grants from Ignyta, grants from IPSEN, grants from Merck / MSD, grants from Nektar, grants from Onxeo, grants from Pfizer, grants from Pharma Mar, grants from Sanofi, grants from Spectrum Pharmaceuticals, grants from Takeda, grants from Tiziana Pharma, non-financial support from Nerviana, non-financial support from GSK, non-financial support from Pfizer, non-financial support from Roche-Genentech, non-financial support from Lilly, non-financial support from OSE pharma, non-financial support from MSD, non-financial support from Cellgene, non-financial support from Stemcentrx, non-financial support from Ignyta, non-financial support from Abbvie, non-financial support from Loxo Oncology, non-financial support from AstraZeneca, non-financial support from Blueprint Medicines, outside the submitted work.